OFA
BTAI

Oaktree Fund Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Oaktree Fund Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
245,585
+202,672
+472% +$237K 0.6% 12
2026
Q1 		$57.5K Hold
42,913
– – 0.1% 14
2025
Q4 		$68.7K Hold
42,913
– – 0.13% 16
2025
Q3 		$110K Hold
42,913
– – 0.2% 17
2025
Q2 		$77.7K Buy
+42,913
New +$71K 0.13% 20

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Oaktree Fund Advisors's BTAI Position: Q2 2026 in Review

Oaktree Fund Advisors increased its BioXcel Therapeutics (BTAI) stake by 472% in Q2 2026, buying an estimated $237K and bringing the position to 245,585 shares worth $346K. The position accounts for 0.6% of the portfolio, ranked #12.

Oaktree Fund Advisors first reported a position in BTAI in Q2 2025 and has held it in 5 quarters since. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Oaktree Fund Advisors held 245,585 shares of BioXcel Therapeutics worth $346K as of Q2 2026.
  • Oaktree Fund Advisors bought 202,672 BioXcel Therapeutics shares in Q2 2026, an estimated $237K.
  • BioXcel Therapeutics made up 0.6% of Oaktree Fund Advisors's portfolio in Q2 2026, its #12 holding.
  • Oaktree Fund Advisors first reported a position in BioXcel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Oaktree Fund Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.